(3Z)-3-(6H-benzo[c][1]benzothiepin-11-ylidene)-N,N-dimethylpropan-1-amine;3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噁庚英
• 英文名称: (3Z)-3-(6H-benzo[c][1]benzothiepin-11-ylidene)-N,N-dimethylpropan-1-amine;3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
• 化学式: C38H42N2OS
• 分子量: 574.8
• InChiKey: VZBFQXSRTQTSCC-JQEYHDMTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.64
• 重原子数：
  42
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  41
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• NMDA RECEPTOR MODULATORS (RAPASTINEL) COMBINATION FOR USE IN COMBINED TREATMENT (SLEEP AND CNS DISORDER)
  申请人：Naurex Inc.

  公开号：EP3720464A1

  公开（公告）日：2020-10-14
• Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
  申请人：PHARMALIGHT INC.

  公开号：US20140171490A1

  公开（公告）日：2014-06-19

  Disclosed is the use of a mist of a pharmaceutical composition for ophthalmic delivery of a protein or peptide active pharmaceutical ingredient, a related method of treatment and a device useful in implementing the use and method. Disclosed is also the use of a mist for ophthalmic delivery of a pharmaceutical composition including a highly irritating penetration enhancer and an ophthalmically acceptable carrier, a related method of treatment and a device useful in implementing the use and method. Disclosed is also a device for ophthalmic administration configured to direct a mist of a pharmaceutical composition to the eye only when the eye is open. Disclosed is also a self-sterlizing device for ophthalmic administration. Disclosed is also a device and a method for increasing the bioavailability of an ophthalmically administered API in a pharmaceutical composition.
• TREATMENT WITH NMDA RECEPTOR MODULATORS
  申请人：Naurex Inc.

  公开号：US20200197365A1

  公开（公告）日：2020-06-25

  Disclosed are methods for treating a patient suffering from (i) a cognitive, neurological or psychological disease or disorder; and (ii) a sleep disorder comprising the step of administering to said patient a therapeutically effective amount of an N-Methyl-D-aspartic acid (NMDA) receptor partial agonist, in particular rapastinel or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof.
• [EN] NMDA RECEPTOR MODULATORS (RAPASTINEL) COMBINATION FOR USE IN COMBINED TREATMENT (SLEEP AND CNS DISORDER)<br/>[FR] COMBINAISON DE MODULATEURS DU RÉCEPTEUR NMDA (RAPASTINEL) POUR UNE UTILISATION DANS UN TRAITEMENT COMBINÉ (TROUBLES DU SOMMEIL ET DU SNC)
  申请人：NAUREX INC

  公开号：WO2019113102A1

  公开（公告）日：2019-06-13

  Disclosed are methods for treating a patient suffering from (i) a cognitive, neurological or psychological disease or disorder; and (ii) a sleep disorder comprising the step of administering to said patient a therapeutically effective amount of an N-Methyl-D-aspartic acid (NMDA) receptor partial agonist, in particular rapastinel or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof.